AIRLINK 74.64 Decreased By ▼ -0.21 (-0.28%)
BOP 5.01 Increased By ▲ 0.03 (0.6%)
CNERGY 4.51 Increased By ▲ 0.02 (0.45%)
DFML 42.44 Increased By ▲ 2.44 (6.1%)
DGKC 87.02 Increased By ▲ 0.67 (0.78%)
FCCL 21.58 Increased By ▲ 0.22 (1.03%)
FFBL 33.54 Decreased By ▼ -0.31 (-0.92%)
FFL 9.66 Decreased By ▼ -0.06 (-0.62%)
GGL 10.43 Decreased By ▼ -0.02 (-0.19%)
HBL 114.29 Increased By ▲ 1.55 (1.37%)
HUBC 139.94 Increased By ▲ 2.50 (1.82%)
HUMNL 12.25 Increased By ▲ 0.83 (7.27%)
KEL 5.21 Decreased By ▼ -0.07 (-1.33%)
KOSM 4.50 Decreased By ▼ -0.13 (-2.81%)
MLCF 38.09 Increased By ▲ 0.29 (0.77%)
OGDC 139.16 Decreased By ▼ -0.34 (-0.24%)
PAEL 25.87 Increased By ▲ 0.26 (1.02%)
PIAA 22.20 Increased By ▲ 1.52 (7.35%)
PIBTL 6.80 No Change ▼ 0.00 (0%)
PPL 123.58 Increased By ▲ 1.38 (1.13%)
PRL 26.81 Increased By ▲ 0.23 (0.87%)
PTC 14.01 Decreased By ▼ -0.04 (-0.28%)
SEARL 58.53 Decreased By ▼ -0.45 (-0.76%)
SNGP 68.01 Decreased By ▼ -0.94 (-1.36%)
SSGC 10.47 Increased By ▲ 0.17 (1.65%)
TELE 8.39 Increased By ▲ 0.01 (0.12%)
TPLP 11.05 Decreased By ▼ -0.01 (-0.09%)
TRG 63.21 Decreased By ▼ -0.98 (-1.53%)
UNITY 26.59 Increased By ▲ 0.04 (0.15%)
WTL 1.42 Decreased By ▼ -0.03 (-2.07%)
BR100 7,943 Increased By 105.5 (1.35%)
BR30 25,639 Increased By 187.1 (0.73%)
KSE100 75,983 Increased By 868.6 (1.16%)
KSE30 24,445 Increased By 330.8 (1.37%)
World

US authorizes first at-home Covid test, results in 20 minutes

  • Commissioner of the Food and Drug Administration said the emergency use authorization represented a "major milestone."
Published December 16, 2020

WASHINGTON: The United States on Tuesday authorized its first rapid at-home test for Covid-19, which is available over-the-counter and produces a result in around 20 minutes.

The test, made by California-based Ellume, will sell for around $30 and the company plans to roll out three million units in January 2021, and millions more in subsequent months.

Stephen Hahn, commissioner of the Food and Drug Administration, said the emergency use authorization represented a "major milestone."

"We are helping expand Americans' access to testing, reducing the burden on laboratories and test supplies, and giving Americans more testing options from the comfort and safety of their own homes," he said.

It is an "antigen" test, meaning it works by detecting a surface molecule of the coronavirus, unlike the more common PCR tests that look for the virus' genetic material.

The technology involved is similar to a home pregnancy test.

The Ellume test uses a nasal swab that doesn't go as far back as the nasopharyngeal swabs used in clinical settings, and is therefore more comfortable to self-administer.

The sample is then inserted into a single-use cartridge.

According to the FDA, it correctly identified 96 percent of positive samples and 100 percent of negative samples in individuals with symptoms.

In people without symptoms, the test correctly identified 91 percent of positive samples and 96 percent of negative samples.

The FDA said that for patients without symptoms, "positive results should be treated as presumptively positive until confirmed by another test as soon as possible."

It added that individuals with positive results should self-isolate and seek additional care from their health care provider, while people who test negative but experience Covid symptoms should also seek follow up with their health care provider.

The home test connects with an app on the user's smartphone to interpret the results.

Results take as little as 20 minutes and are delivered via the app, which requires users to input their zip code and date of birth, to report to public health authorities.

Providing the name and email address is optional.

Ellume developed the test with $30 million in government funding from the National Institutes of Health.

Comments

Comments are closed.